查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
BPH 治疗市场：2019-2029 年全球市场规模、份额、趋势分析、机会和预测报告
市场调查报告书
商品编码
1310371

BPH 治疗市场：2019-2029 年全球市场规模、份额、趋势分析、机会和预测报告

Benign Prostatic Hyperplasia Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Therapy ; By Therapeutic Class ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到2029年全球良性前列腺增生（BPH）治疗市场将达到74亿美元

全球良性前列腺增生（BPH）治疗市场受到全球BPH患病率不断上升、易患BPH的老年人口不断增加以及微创治疗方案进步的推动，因此正在蓬勃发展。

领先的战略咨询和市场研究公司 BlueWeave Consulting 最近的一项研究估计，2022 年全球良性前列腺增生 (BPH) 治疗市场价值将达到 59.7797 亿美元。 BlueWeave预测，在2023-2029年的预测期内，全球前列腺增生症治疗市场规模将以3.13%的复合年复合成长率稳定增长，到2029年达到73.8199亿美元。全球良性前列腺增生（BPH）治疗市场的主要增长促进因素包括提高公众对可用治疗方案的认识。诸如经尿道前列腺电切术（TURP）的引入等技术进步也在推动市场增长方面发挥着关键作用。 TURP 是一种内窥镜电外科手术，可切除部分前列腺以缓解生长引起的阻塞。个人医疗保健支出能力的提高和医疗保健基础设施的显着改善，尤其是在新兴国家，预计将进一步推动市场的扩张。良性前列腺增生及其相关泌尿系统疾病患病率的增加是市场增长的重要促进因素。炎症反应增加、交感神经活动和氧化应激等因素会导致 BPH 的发生，尤其是在肥胖患者中。体内荷尔蒙的变化也与BPH以及BPH的发展有关，扩大了BPH药物的市场。此外，由于医疗保健基础设施的改善、未满足的医疗保健需求的增加以及研发 (R&D) 力度的加大，尚未开发的新兴经济体提供了巨大的市场发展机会。因此，这些方面预计将在分析期间推动全球良性前列腺增生症市场的扩张。然而，与 BPH 治疗程序相关的高成本以及与某些治疗方案相关的副作用和并发症预计将在预测期内抑制整个市场的增长。

该报告的详细分析提供了有关全球良性前列腺增生治疗市场的增长潜力、未来趋势和统计数据的信息。它还揭示了推动整体市场规模预测的因素。该报告致力于为决策者提供全球良性前列腺增生治疗市场的最新技术趋势以及行业见解，以做出明智的战略决策。它还分析了市场的增长促进因素、挑战和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球良性前列腺增生（BPH）治疗市场洞察

  • 行业价值链分析
  • DROC分析
    • 增长动力
      • 全球良性前列腺增生症患病率增加
      • 人口老龄化增加易患良性前列腺增生
      • 微创治疗方案的进展
    • 抑制因素
      • 治疗 BPH 的费用较高
      • 与特定治疗方案相关的副作用和并发症
    • 机会
      • 开发新的、更有效的治疗方案。
      • 加大研发投入。
    • 任务
      • 市场相关人员之间的激烈竞争
      • 部分地区先进治理技术引进滞后
  • 技术进步/最新发展
  • 监管框架
  • 波特五力分析

第4章全球良性前列腺增生（BPH）治疗市场概述

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
      • 单一疗法
      • 伴随药物治疗
    • 按治疗类别
      • α阻滞剂
      • 5-α-还原酶抑製剂
      • 磷酸二酯酶5抑製剂
      • 其他的
    • 按地区
      • 北美
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第5章北美良性前列腺增生（BPH）治疗市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按治疗类别
    • 按国家/地区
      • 我们
      • 加拿大

第6章欧洲良性前列腺增生（BPH）治疗市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按治疗类别
    • 按国家/地区
      • 德国
      • 英国
      • 意大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第7章亚太良性前列腺增生（BPH）治疗市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按治疗类别
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳大利亚和新西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他国家

第8章拉丁美洲良性前列腺增生（BPH）治疗市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按治疗类别
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 拉丁美洲其他地区

第9章中东和非洲良性前列腺增生（BPH）治疗市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场份额及预测
    • 通过治疗
    • 按治疗类别
    • 按国家/地区
      • 沙特阿拉伯
      • 阿拉伯联合酋长国
      • 卡塔尔
      • 科威特
      • 南非
      • 尼日利亚
      • 阿尔及利亚
      • MEA 的其余部分

第10章竞争格局

  • 主要公司及其产品列表
  • 2022 年全球良性前列腺增生 (BPH) 治疗市场份额分析
  • 通过管理参数进行竞争基准测试
  • 主要战略发展（合併、收购、合作伙伴关係等）

第11章COVID-19 感染对全球 BPH（BPH）治疗市场的影响

第12章公司简介（公司简介、财务矩阵、竞争格局、关键人才、主要竞争、联繫地址、战略展望、SWOT分析）

  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Johnson & Johnson
  • Pfizer Inc.
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Medtronic plc
  • Urologix, LLC
  • Teleflex Incorporated
  • Olympus Corporation
  • Merck & Co., Inc.
  • Allergan plc
  • Endo International plc
  • Other Prominent Players

第13章关键战略建议

第14章调查方法

简介目录
Product Code: BWC22256

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Set to Touch USD 7.4 Billion by 2029.

Global benign prostatic hyperplasia (BPH) treatment market is flourishing, because of increasing prevalence of BPH across the world, growing geriatric population prone to BPH, and advancements in minimally invasive treatment options.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global benign prostatic hyperplasia (BPH) treatment market size at USD 5,977.97 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global benign prostatic hyperplasia (BPH) treatment market size to grow at a steady CAGR of 3.13% reaching a value of USD 7,381.99 million by 2029. Major growth drivers for the global benign prostatic hyperplasia (BPH) treatment market include an increasing awareness among the public regarding available treatment options. Technological advancements, such as the introduction of transurethral resection of the prostate (TURP), have also played a significant role in driving market growth. TURP is an endoscopic electrosurgical procedure that involves the removal of a portion of the prostate gland to alleviate blockage caused by abnormal growth. The expanding individual healthcare expenditure capacities and notable improvements in healthcare infrastructure, particularly in developing countries, are expected to further propel the market's expansion. The growing prevalence of benign prostatic hyperplasia and the associated urological conditions are significant drivers of market growth. Factors such as elevated inflammatory response, sympathetic nerve activity, and oxidative stress contribute to the development of BPH, particularly in obese patients. Hormonal changes in the body are also linked to prostate enlargement and the development of BPH, thereby expanding the market for BPH medications. Also, untapped emerging economies present significant opportunities for market development due to improved healthcare infrastructure, a growing demand for unmet healthcare needs, and increased efforts in research and development (R&D). Hence, such aspects are expected to boost the expansion of global BPH market during the period in analysis. However, high costs associated with BPH treatment procedures and adverse effects and complications associated with certain treatment options are anticipated to restrain the growth of overall market during the forecast period.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - Overview:

Benign prostatic hyperplasia (BPH), commonly referred to as the enlargement of the prostate gland, tends to become more prevalent in aging men. An enlarged prostate gland can lead to urinary symptoms, such as urinary retention, and may also affect the bladder, urethra, or kidneys. Treatment options for BPH encompass a range of approaches, including prescription medications, active surveillance, monotherapy and combination therapy, phytotherapy, as well as minimally invasive and invasive surgeries. These procedures often involve the utilization of resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. Active surveillance serves as one of the primary treatment methods for BPH. This approach entails closely monitoring the condition without active intervention. Under the guidance of a urologist, regular monitoring of the BPH will take place, typically through annual physical examinations. The focus will be on identifying any new or worsening symptoms before considering further interventions. Additionally, lifestyle modifications, including dietary adjustments and exercise, are commonly recommended to prevent or manage symptoms. Active surveillance is typically suitable for men experiencing mild to moderate symptoms or those who are not significantly bothered by BPH symptoms. However, if symptoms worsen or new ones emerge, the healthcare provider may recommend transitioning to active therapy.

Impact of COVID-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market:

COVID-19 pandemic adversely affected global benign prostatic hyperplasia (BPH) treatment market. The healthcare system's focus on managing and containing the virus has resulted in a redirection of resources, affecting the diagnosis and treatment of non-emergency conditions, such as BPH. Delayed elective surgeries, reduced outpatient visits, and disruptions in the supply chain of medications and medical devices have impacted the market. Moreover, the economic impact of the pandemic has led to financial constraints for individuals, affecting their ability to seek timely BPH treatment. However, with the gradual resumption of healthcare services and the development of vaccination programs, the market recovered in the post-pandemic period, with a renewed emphasis on addressing the unmet needs of BPH patients.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - By Therapy:

By therapy, the global benign prostatic hyperplasia (BPH) treatment market is bifurcated into Mono Drug Therapy and Combination Drug Therapy segments. The combination drug therapy segment holds a higher market share in the global benign prostatic hyperplasia (BPH) treatment market, due to its enhanced efficacy and comprehensive approach. By combining medications with different mechanisms of action, combination therapy offers improved symptom relief and better outcomes compared to mono drug therapy. The synergistic effects of combined drugs further contribute to its popularity among healthcare providers and patients. Treatment guidelines and recommendations endorsing combination therapy, along with patient preferences for convenience, also drive its market dominance. Streamlining multiple medications into a single combination product enhances medication adherence and patient compliance. These factors collectively contribute to the prominence of combination drug therapy in the BPH treatment market.

Competitive Landscape:

Major players operating in the global benign prostatic hyperplasia (BPH) treatment market include: Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, and Endo International plc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Benign Prostatic Hyperplasia (BPH) Treatment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Benign Prostatic Hyperplasia (BPH) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of BPH globally.
      • 3.2.1.2. Growing ageing population prone to BPH.
      • 3.2.1.3. Advancements in minimally invasive treatment options.
    • 3.2.2. Restraints
      • 3.2.2.1. High costs associated with BPH treatment procedures
      • 3.2.2.2. Adverse effects and complications associated with certain treatment options
  • 3.3. Opportunities
      • 3.3.1.1. Development of novel and more effective treatment options.
      • 3.3.1.2. Increasing investment in research and development.
    • 3.3.2. Challenges
      • 3.3.2.1. Intense competition among market players.
      • 3.3.2.2. Slow adoption of advanced treatment technologies in certain regions.
  • 3.4. Technology Advancements/Recent Developments
  • 3.5. Regulatory Framework
  • 3.6. Porter's Five Forces Analysis
    • 3.6.1. Bargaining Power of Suppliers
    • 3.6.2. Bargaining Power of Buyers
    • 3.6.3. Threat of New Entrants
    • 3.6.4. Threat of Substitutes
    • 3.6.5. Intensity of Rivalry

4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Therapy
      • 4.2.1.1. Mono drug therapy
      • 4.2.1.2. Combination drug therapy
    • 4.2.2. By Therapeutic Class
      • 4.2.2.1. Alpha blockers
      • 4.2.2.2. 5- alpha-reductase inhibitors
      • 4.2.2.3. Phosphodiesterase-5 inhibitors
      • 4.2.2.4. Others
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia Pacific (APAC)
      • 4.2.3.4. Latin America (LATAM)
      • 4.2.3.5. Middle East and Africa (MEA)

5. North America Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy
    • 5.2.2. By Therapeutic Class
    • 5.2.3. By Country
      • 5.2.3.1. United States
      • 5.2.3.1.1. By Therapy
      • 5.2.3.1.2. By Therapeutic Class
      • 5.2.3.2. Canada
      • 5.2.3.2.1. By Therapy
      • 5.2.3.2.2. By Therapeutic Class

6. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Therapeutic Class
    • 6.2.3. By Country
      • 6.2.3.1. Germany
      • 6.2.3.1.1. By Therapy
      • 6.2.3.1.2. By Therapeutic Class
      • 6.2.3.2. United Kingdom
      • 6.2.3.2.1. By Therapy
      • 6.2.3.2.2. By Therapeutic Class
      • 6.2.3.3. Italy
      • 6.2.3.3.1. By Therapy
      • 6.2.3.3.2. By Therapeutic Class
      • 6.2.3.4. France
      • 6.2.3.4.1. By Therapy
      • 6.2.3.4.2. By Therapeutic Class
      • 6.2.3.5. Spain
      • 6.2.3.5.1. By Therapy
      • 6.2.3.5.2. By Therapeutic Class
      • 6.2.3.6. Belgium
      • 6.2.3.6.1. By Therapy
      • 6.2.3.6.2. By Therapeutic Class
      • 6.2.3.7. Russia
      • 6.2.3.7.1. By Therapy
      • 6.2.3.7.2. By Therapeutic Class
      • 6.2.3.8. The Netherlands
      • 6.2.3.8.1. By Therapy
      • 6.2.3.8.2. By Therapeutic Class
      • 6.2.3.9. Rest of Europe
      • 6.2.3.9.1. By Therapy
      • 6.2.3.9.2. By Therapeutic Class

7. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Therapeutic Class
    • 7.2.3. By Country
      • 7.2.3.1. China
      • 7.2.3.1.1. By Therapy
      • 7.2.3.1.2. By Therapeutic Class
      • 7.2.3.2. India
      • 7.2.3.2.1. By Therapy
      • 7.2.3.2.2. By Therapeutic Class
      • 7.2.3.3. Japan
      • 7.2.3.3.1. By Therapy
      • 7.2.3.3.2. By Therapeutic Class
      • 7.2.3.4. South Korea
      • 7.2.3.4.1. By Therapy
      • 7.2.3.4.2. By Therapeutic Class
      • 7.2.3.5. Australia & New Zealand
      • 7.2.3.5.1. By Therapy
      • 7.2.3.5.2. By Therapeutic Class
      • 7.2.3.6. Indonesia
      • 7.2.3.6.1. By Therapy
      • 7.2.3.6.2. By Therapeutic Class
      • 7.2.3.7. Malaysia
      • 7.2.3.7.1. By Therapy
      • 7.2.3.7.2. By Therapeutic Class
      • 7.2.3.8. Singapore
      • 7.2.3.8.1. By Therapy
      • 7.2.3.8.2. By Therapeutic Class
      • 7.2.3.9. Vietnam
      • 7.2.3.9.1. By Therapy
      • 7.2.3.9.2. By Therapeutic Class
      • 7.2.3.10. Rest of APAC
      • 7.2.3.10.1. By Therapy
      • 7.2.3.10.2. By Therapeutic Class

8. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Therapeutic Class
    • 8.2.3. By Country
      • 8.2.3.1. Brazil
      • 8.2.3.1.1. By Therapy
      • 8.2.3.1.2. By Therapeutic Class
      • 8.2.3.2. Mexico
      • 8.2.3.2.1. By Therapy
      • 8.2.3.2.2. By Therapeutic Class
      • 8.2.3.3. Argentina
      • 8.2.3.3.1. By Therapy
      • 8.2.3.3.2. By Therapeutic Class
      • 8.2.3.4. Peru
      • 8.2.3.4.1. By Therapy
      • 8.2.3.4.2. By Therapeutic Class
      • 8.2.3.5. Rest of LATAM
      • 8.2.3.5.1. By Therapy
      • 8.2.3.5.2. By Therapeutic Class

9. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Therapeutic Class
    • 9.2.3. By Country
      • 9.2.3.1. Saudi Arabia
      • 9.2.3.1.1. By Therapy
      • 9.2.3.1.2. By Therapeutic Class
      • 9.2.3.2. UAE
      • 9.2.3.2.1. By Therapy
      • 9.2.3.2.2. By Therapeutic Class
      • 9.2.3.3. Qatar
      • 9.2.3.3.1. By Therapy
      • 9.2.3.3.2. By Therapeutic Class
      • 9.2.3.4. Kuwait
      • 9.2.3.4.1. By Therapy
      • 9.2.3.4.2. By Therapeutic Class
      • 9.2.3.5. South Africa
      • 9.2.3.5.1. By Therapy
      • 9.2.3.5.2. By Therapeutic Class
      • 9.2.3.6. Nigeria
      • 9.2.3.6.1. By Therapy
      • 9.2.3.6.2. By Therapeutic Class
      • 9.2.3.7. Algeria
      • 9.2.3.7.1. By Therapy
      • 9.2.3.7.2. By Therapeutic Class
      • 9.2.3.8. Rest of MEA
      • 9.2.3.8.1. By Therapy
      • 9.2.3.8.2. By Therapeutic Class

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Astellas Pharma Inc.
  • 12.2. Eli Lilly and Company
  • 12.3. GlaxoSmithKline plc
  • 12.4. AstraZeneca plc
  • 12.5. Johnson & Johnson
  • 12.6. Pfizer Inc.
  • 12.7. Abbott Laboratories
  • 12.8. Boston Scientific Corporation
  • 12.9. Medtronic plc
  • 12.10. Urologix, LLC
  • 12.11. Teleflex Incorporated
  • 12.12. Olympus Corporation
  • 12.13. Merck & Co., Inc.
  • 12.14. Allergan plc
  • 12.15. Endo International plc
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations